Guillermo Villacampa: Meta-analysis evaluating immunotherapy in early breast cancer
Recently, an article by Guillermo Villacampa et al. was published in JAMA Oncology.
Authors: Guillermo Villacampa, Victor Navarro, Alexios Matikas, Aleix Prat, Mafalda Oliveira, Tomás Pascual et al.
Oncologists shared this article, commenting on social media:
Guillermo Villacampa, Biostatistician at Vall d’Hebron Institute of Oncology:
“Extremely happy to share this meta-analysis evaluating immunotherapy in early breast cancer in JAMA Oncology.
Thanks, Tomás Pascual for the guidance.
Thanks, Elizabeth Mittendorf and Sara Tolaney for writing the editorial.
The study combines existing evidence trying to clarify:
- Role of PD-L1 as a prognostic/predictive biomarker.
- ICI efficacy in different molecular phenotypes.
- Contribution of adjuvant ICI in pts with and without pCR.
- Safety implications of ICI.”
Aleix Prat, Head Oncology at Hospital Clínic:
“Our new research article is out in JAMA Oncology!
Led by Guillermo Villacampa and Tomás Pascual.
Our study shows that neoadjuvant immune checkpoint inhibitors (ICIs) improve outcomes in early-stage TNBC and PD-L1+ HR+/HER2− breast cancers.
However, no benefits were seen with adjuvant ICI therapy.
Future research should focus on identifying patients who will benefit most, given the costs and potential side effects of ICIs biomarkers? Stay tuned for that at ESMO24.
Editorial by Elizabeth Mittendorf and Sara Tolaney.”
More posts featuring Guillermo Villacampa on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023